Skip to main content

Table 5 Uni- and multivariate analysis regarding local failure, distant brain failure and overall survival

From: Impact of regular magnetic resonance imaging follow-up after stereotactic radiotherapy to the surgical cavity in patients with one to three brain metastases

 

Univariate

Multivariate

HR (95% CI)

p-value

HR (95% CI)

p-value

Local failure

 Gender

1.26 (0.57–2.77)

0.573

  

 Age

1 (0.97–1.04)

0.912

  

 Histology

1.08 (0.83–1.4)

0.576

  

 Residual tumor

1.22 (0.42–3.58)

0.712

1.55 (0.47–5.1)

0.475

 GPA score

0.66 (0.36–1.21)

0.18

0.82 (0.42–1.59)

0.552

 PTVres > 15 cm3

3.42 (1.54–7.62)

0.003

3.2 (1.37–7.48)

0.007

 BED < 40 Gy

6.33 (2.5–15.9)

< 0.001

5.71 (2.05–15.9)

0.001

 MRI FU at 3 months

0.97 (0.43–2.16)

0.936

0.96 (0.39–2.37)

0.926

 ≥ 1 MRI per 180 days

1.4 (0.63–3.14)

0.412

  

Distant brain failure

 Gender

1.18 (0.62–2.24)

0.61

  

 Age

1.02 (0.99–1.05)

0.201

  

 Histology

1.07 (0.87–1.32)

0.535

  

 Residual tumor

1.26 (0.58–2.73)

0.559

1.52 (0.67–3.45)

0.322

 GPA score

0.42 (0.26–0.67)

< 0.001

0.46 (0.28–0.74)

0.001

 PTVres > 15 cm3

3.7 (1.97–6.97)

< 0.001

3.18 (1.34–6.16)

0.001

 BED < 40 Gy

2.1 (0.78–5.68)

0.143

1.31 (0.45–3.8)

0.623

 MRI FU at 3 months

0.97 (0.52–1.81)

0.912

1.19 (0.59–2.38)

0.628

 ≥ 1 MRI per 180 days

1.44 (0.76–2.71)

0.262

  

Overall survival

 Gender

1.57 (0.86–2.88)

0.141

  

 Age

1.01 (0.98–1.04)

0.637

  

 Histology

1.65 (0.96–1.41)

0.115

  

 Residual tumor

2.91 (1.58–5.38)

0.001

2.4 (1.29–5.64)

0.008

 GPA score

0.39 (0.24–0.62)

< 0.001

0.42 (0.26–0.69)

0.001

 PTVres > 15 cm3

2.67 (1.47–4.85)

0.001

2.29 (1.22–4.31)

0.01

 BED < 40 Gy

3.38 (1.31–8.7)

0.012

2.28 (0.82–6.33)

0.113

 MRI FU at 3 months

0.8 (0.44–1.45)

0.461

1 (0.52–1.92)

0.993

 ≥ 1 MRI per 180 days

1.5 (0.83–2.72)

0.183

  
  1. HR hazard ratio, CI confidence interval, GPA Graded Prognostic Assessment, PTVres planning target volume, BED biologically effective dose, MRI FU magnetic resonance imaging follow-up